Virtuozzo Acquires OnApp, Enabling More Comprehensive Intuitive Cloud Infrastructure Solutions for Service Providers
Virtuozzo’s mission is to help shape the future of the cloud by empowering service providers with comprehensive, high performance, flexible and easy-to-use cloud infrastructure solutions supporting private, public and hybrid cloud use cases. To that end, Virtuozzo, a global leader in high-efficiency virtualization and hyperconverged software solutions, today announced it is acquiring OnApp, a London-based software company focused on cloud solutions for service providers. The acquisition augments Virtuozzo’s existing cloud IaaS and PaaS products while expanding its regional market reach.
Future-proofed Cloud Flexibility, Simplicity and Automation
The combined technological and R&D strengths of both companies directly target the evolving needs of Cloud Service Providers (CSPs), Managed Service Providers (MSPs), and Hosting Providers focused on providing IaaS, PaaS and XaaS solutions for their customers.
The resulting solution stack will pair Virtuozzo’s easy-to-use virtualization, containerization, storage and orchestration capabilities with advanced features of OnApp’s flexible self-service management platform. In turn, service providers will gain access to today’s most intuitive and robust cloud infrastructure and platform solutions capable of supporting any cloud use case.
“Virtuozzo’s primary expertise has traditionally been in high-density server virtualization and software-defined storage. We have successfully expanded over the last few years into hyperconverged infrastructure as it is crucial to the market’s evolution,” said Alex Fine, Virtuozzo CEO. “Simple, flexible and smart access to those strong, fundamental technologies is core to the success of MSPs, CSPs and Hosting Providers and therefore, core to ours. OnApp shares that commitment and brings to Virtuozzo incredible engineering talent and complementary technologies that help us advance the cloud infrastructure industry as a whole. We’re proud and excited to have the OnApp team on board.”
Market Growth Driving Innovation
Timing and demand are key factors behind the acquisition. Synergy Research Group recently reported that cloud infrastructure demand reached $129 billion in 2020, growing 35% year over year. About a third of this market is owned by non-hyperscalers—local, regional and multi-national service providers. Those providers are the beneficiaries of Virtuozzo technology.
In parallel, 451 Research, a part of S&P Global Market Intelligence, recently discussed in its 2021 analysis Demand and Opportunity in the Alternative Cloud Provider Market a potential new opportunity for alternative CSPs, noting that they may find a role in larger multi-cloud portfolios and that “alternative can mean ‘in addition to’ rather than ‘instead of.’”1 Collectively, these reports suggest that alternative CSPs and MSPs are well-positioned to become partners of choice for customers shifting to modern cloud services.
“In addition to OnApp technical expertise in cloud orchestration, user interface and content delivery networks, Virtuozzo sees the value our highly talented staff brings to the table,” stated Ditlev Bredahl, CEO, OnApp. “Integration and evolution of the joint solution stack will be strongly beneficial to the customers of both companies.”
Terms of the transaction were not disclosed. Per the agreement, OnApp will continue operation as a division of Virtuozzo with OnApp’s staff integrating into Virtuozzo’s organizational structure. Business will continue as usual with Bredahl assisting with post-acquisition integration.
About OnApp
OnApp provides software and services that enable hosts, MSPs and telecoms providers to create and sell their own public, private and hybrid clouds. OnApp launched in July 2010, and to date has deployed more than 6,000 clouds for service providers in 93 countries. OnApp has 130 staff across the EU, U.S. and Asia-Pacific and is headquartered in London, UK. For more information, visit https://onapp.com.
About Virtuozzo
Virtuozzo (www.virtuozzo.com) is a leading, global provider of hybrid virtualization, storage, and cloud enablement software solutions. The Company's software-defined, hyperconverged self-service platform and resource management capabilities enable hosting and service providers to provide end-customers with public and private cloud services. Virtuozzo is an industry pioneer who developed the first commercially available container technology 21 years ago. The Company provides software solutions and services to over 450 service providers, ISVs, and enterprises worldwide to enable over 500 thousand virtual environments, running mission-critical cloud workloads. A significant force in the open-source community, Virtuozzo sponsors and/or is a contributor to numerous open-source projects including KVM, Docker, OpenStack, OpenVZ, CRIU, and the Linux kernel.
1 Demand and Opportunity in the Alternative Cloud Provider Market, Liam Eagle, 451 Research, a part of S&P Global Market Intelligence. January 2021.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210720005004/en/
Contact information
Heather Ailara/Deb Brown
211 Communications
+1.973.567.6040
heather@211comms.com
/
deb@211comms.com
Christine Brunelli
Virtuozzo
+1 215-847-7842
christine.brunelli@virtuozzo.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
